-
公开(公告)号：US20150233945A1
公开(公告)日：2015-08-20
申请号：US14705299
申请日：2015-05-06
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Dirk Block , Julian Braz , Hans-Peter Brunner , James Creeden , Hans-Juergen Loyda , Ursula-Henrike Wienhues-Thelen , Christian Zaugg
IPC: G01N33/68
CPC classification number: G01N33/6887 , G01N33/6893 , G01N2333/47 , G01N2333/58 , G01N2800/325 , G01N2800/52
Abstract: The present invention relates to a method for guiding heart failure treatment in a subject suffering from heart failure. The method is based on the determination of the amount of a BNP-type peptide and a cardiac troponin in a sample from said subject. Further envisaged by the present invention are kits and devices adapted to carry out the present invention. The present invention also relates to a system for guiding heart failure treatment in a subject suffering from heart failure as disclosed herein and to reagents and kits used in performing the methods disclosed herein.
Abstract translation: 本发明涉及一种在患有心力衰竭的受试者中引导心力衰竭治疗的方法。 该方法基于来自所述受试者的样品中BNP型肽和心肌肌钙蛋白的量的测定。 本发明进一步设想的是适用于实施本发明的试剂盒和装置。 本发明还涉及用于指导本文公开的患有心力衰竭的受试者的心力衰竭治疗的系统以及用于执行本文公开的方法的试剂和试剂盒。
-
公开(公告)号：US20150185230A1
公开(公告)日：2015-07-02
申请号：US14644695
申请日：2015-03-11
Applicant: Roche Diagnostics Operations, Inc
Inventor： Dirk Block , Roberto Latini , Serge Masson , Ursula-Henrike Wienhues-Thelen , Christian Zaugg
CPC classification number: G01N33/6887 , A61B5/055 , A61B8/0883 , G01N33/82 , G01N2333/4703 , G01N2333/4706 , G01N2333/4712 , G01N2333/50 , G01N2333/78 , G01N2800/32 , G01N2800/329 , G01N2800/50
Abstract: The present invention relates to a method for assessing whether a subject shall be subjected to an imaging based diagnostic assessment. The method is based on the determination of the amount(s) of a cardiac Troponin and/or Fibroblast Growth Factor 23 (FGF-23) in a sample from the subject, and on the comparison of the, thus, determined amount(s) with a reference amount (reference amounts). The present invention also relates to a system for performing an assessment whether a subject shall be subjected to an imaging based diagnostic assessment and to reagents and kits used in performing the methods disclosed herein. Moreover, the present invention is directed to a method for predicting the risk of mortality and/or of a cardiovascular event. Also encompassed is a method for diagnosing an early stage of LVH in a subject having a preserved left ventricular ejection.
Abstract translation: 本发明涉及一种用于评估受试者是否应进行基于成像的诊断评估的方法。 该方法基于来自受试者的样品中心肌肌钙蛋白和/或成纤维细胞生长因子23（FGF-23）的量的测定，以及因此确定的量（s） 具有参考量（参考量）。 本发明还涉及一种用于执行评估受试者是否应进行基于成像的诊断评估的系统以及用于执行本文所公开的方法的试剂和试剂盒。 此外，本发明涉及一种用于预测死亡风险和/或心血管事件风险的方法。 还包括用于诊断具有保留的左心室射血的受试者的LVH的早期阶段的方法。
-
33.发明申请USE OF BIOMARKERS IN THE ASSESSMENT OF THE EARLY TRANSITION FROM ARTERIAL HYPERTENSION TO HEART FAILURE 审中-公开生物标记在评估从早期转移到心脏失效的早期转换中的使用公开(公告)号：US20140065648A1
公开(公告)日：2014-03-06
申请号：US13776314
申请日：2013-02-25
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Ursula-Henrike Wienhues-Thelen , Dirk Block , Hendrik Heudig , Sabine Vogel-Ziebolz , Christine Boehm , Georg Hess , Andrea Horsch , Dietmar Zdunek
IPC: G01N33/68
CPC classification number: G01N33/54306 , G01N33/6887 , G01N33/6893 , G01N2333/4712 , G01N2333/495 , G01N2333/58 , G01N2800/325 , G01N2800/50 , G01N2800/52
Abstract: Methods and systems for diagnosing functional and/or structural abnormalities of the heart preceding heart failure, and for predicting the risk of developing heart failure, in a subject comprising measuring a cardiac troponin in a sample and comparing the measurement to a reference value. Other markers, including GDF15 and IGFBP7 are also measured in some embodiments.
Abstract translation: 用于诊断心脏衰竭前的心脏的功能和/或结构异常以及用于预测心脏衰竭发展的风险的方法和系统，包括测量样品中的心肌肌钙蛋白并将测量值与参考值进行比较。 在一些实施方案中也测量了其它标志物，包括GDF15和IGFBP7。
-
公开(公告)号：US11874282B2
公开(公告)日：2024-01-16
申请号：US16110687
申请日：2018-08-23
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Martin Hund , Edelgard Anna Kaiser , Ursula-Henrike Wienhues-Thelen , Dirk Block , Johann Karl
CPC classification number: G01N33/689 , G01N33/6893 , G16B20/00 , G16B25/10 , G16B99/00 , G01N2333/4703 , G01N2333/4745 , G01N2800/368 , G01N2800/52 , G01N2800/60
Abstract: The present disclosure relates to a method for diagnosing preeclampsia or a preeclampsia-related condition in a pregnant subject. The method is based on the measurement of the amount of the biomarker IGFBP-7 (Insulin-like Growth Factor Binding Protein 7) in a sample from the subject and on the comparison of the measured amount to a reference. Also disclosed are methods for assessing the severity of preeclampsia or a preeclampsia-related condition and methods for monitoring a preeclampsia or a preeclampsia-related condition in a pregnant subject. The present disclosure further relates to the use of the biomarker IGFBP-7 or of an agent that specifically binds to IGFBP-7 in a sample from a pregnant subject for diagnosing, for monitoring or for assessing the severity of preeclampsia or a preeclampsia-related condition. Finally, the present disclosure relates to a device or kit adapted to carry out the method of the present invention.
-
公开(公告)号：US20230062697A1
公开(公告)日：2023-03-02
申请号：US17821951
申请日：2022-08-24
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Dirk Block , Roberto Latini , Serge Masson , Ursula-Henrike Wienhues-Thelen , Christian Zaugg , Andre Ziegler
Abstract: The present invention relates to a method for diagnosing a recent paroxysmal atrial fibrillation. The method is based on the determination of the at least one marker selected from the group consisting of a cardiac Troponin, NT-proBNP (N-terminal prohormone of brain natriuretic peptide), hsCRP, IL-6 (Interleukin-6) and IGFBP7 (Insulin like growth factor binding protein 7) in a sample from the subject, and on the comparison of the, thus, determined amount(s) with a reference amount (reference amounts). Further, the present invention relates to a method for identifying a subject being treatable with anticoagulation therapy. Further envisaged are systems, reagents and kits used in performing the methods disclosed herein.
-
Patent Agency Ranking
36.发明申请公开(公告)号：US20190353666A1
公开(公告)日：2019-11-21
申请号：US16217612
申请日：2018-12-12
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Herbert Andres , Dirk Block , Johann Karl , Peter Kastner , Ursula-Henrike Wienhues-Thelen , Roberto Latini , Serge Masson , Andre Ziegler , Edelgard Kaiser , Stefan Palme , Markus Thomas , Simona Barlera
IPC: G01N33/68
Abstract: The present disclosure relates to a method for predicting the risk of recurrence of Atrial Fibrillation in a subject based on determining the amount of the biomarker Angiopoietin-2 (Ang-2) and optionally of at least one further biomarker in a sample from the subject. The present disclosure also contemplates a method of diagnosing Atrial Fibrillation in a subject suspected to suffer from Atrial Fibrillation based on determining the amount of the biomarker Angiopoietin-2 (Ang-2) and optionally of at least one further biomarker in a sample from the subject. Further envisaged are devices adapted to carry out the method of the present disclosure.
-
公开(公告)号：US20190279770A1
公开(公告)日：2019-09-12
申请号：US16158754
申请日：2018-10-12
Applicant: Roche Diagnostics Operations, Inc. , Institut Lorrain du Coeur et des Vaisseux Louis Mathieu
Inventor： Dirk Block , Ursula-Henrike Wienhues-Thelen , Christian Zaugg , Andre Ziegler , Faiez Zannad , Patrick Rossignol
Abstract: The present disclosure relates to a method of identifying a subject who is at risk of progressing to left ventricular hypertrophy (LVH), using the steps of measuring the amount of the biomarker soluble ST2 and comparing the thus measured amount to a reference. Further encompassed by the present disclosure are kits and devices adapted to carry out the method of the present invention.
-
公开(公告)号：US20170227552A1
公开(公告)日：2017-08-10
申请号：US15581587
申请日：2017-04-28
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Roberto Latini , Serge Masson , Dirk Block , Christian Zaugg , Thomas Dieterle , Edelgard Kaiser , Johann Karl , Vinzent Rolny , Ursula-Henrike Wienhues-Thelen
IPC: G01N33/68
Abstract: The present invention relates to a method for predicting the risk of a subject of rapidly progressing to chronic heart failure and/or of hospitalization due to chronic heart failure and/or death. The method is based on the determination of at least one biomarker selected from the group consisting of a BNP-type peptide, IGFBP7 (IGF binding protein 7), a cardiac Troponin, soluble ST2 (sST2), FGF-23 (Fibroblast Growth Factor 23), and Growth Differentiation Factor 15 (GDF-15), in a sample of a subject. The method may further encompass the assessment of the presence or absence of (i) abnormal midwall fractional shortening or (ii) left ventricular hypertrophy. Further envisaged by the present invention are devices adapted to carry out the present invention.
-
39.发明申请BIOMARKERS FOR RISK ASSESSMENT AND TREATMENT MONITORING IN HEART FAILURE PATIENTS GUIDED BY NATRIURETIC PEPTIDES 审中-公开风险评估和治疗心脏缺陷患者的生物标志物由NATRIURETIC PEPTID指导公开(公告)号：US20160334419A1
公开(公告)日：2016-11-17
申请号：US15220555
申请日：2016-07-27
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Dirk Block , Hans-Peter Brunner , Ursula-Henrike Wienhues-Thelen , Christian Zaugg , Thomas Dieterle , Cheryl Mitchell , Johan Ubby , Sandra Sanders-van Wijk
Abstract: The present invention relates to a method for identifying a patient who is eligible to an intensification of heart failure therapy. Furthermore, the present invention relates to a method for optimizing BNP-type peptide guided heart failure therapy. The methods are based on the measurement of the level of at least one marker in a sample from a patient who has heart failure and who receives BNP-type peptide guided heart failure therapy. Further envisaged by the present invention are kits and devices adapted to carry out the present invention.
Abstract translation: 本发明涉及一种用于识别符合心力衰竭治疗强化的患者的方法。 此外，本发明涉及一种优化BNP型肽引导性心力衰竭治疗的方法。 该方法基于来自患有心力衰竭并且接受BNP型肽引导的心力衰竭治疗的患者的样品中至少一个标记物的水平的测量。 本发明进一步设想的是适用于实施本发明的试剂盒和装置。
-
公开(公告)号：US20160169911A1
公开(公告)日：2016-06-16
申请号：US15054255
申请日：2016-02-26
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Dirk Block , Hanspeter Brunner , Thomas Dieterle , Ursula-Henrike Wienhues-Thelen , Christian Zaugg , Andre Ziegler
CPC classification number: G01N33/6893 , A61K31/40 , G01N33/62 , G01N33/6869 , G01N33/6872 , G01N2333/47 , G01N2333/475 , G01N2333/495 , G01N2333/5412 , G01N2800/325 , G01N2800/52
Abstract: The present invention is directed to a method of identifying a patient having heart failure as likely to respond to a therapy comprising a statin. The method is based on measuring the level of at least one marker selected from GDF-15 (Growth Differentiation Factor 15), Urea, SHBG (Sex Hormone-Binding Globulin), Uric acid, PLGF (Placental Growth Factor), IL-6 (Interleukin-6), Transferrin, a cardiac Troponin, sFlt-1 (Soluble fms-like tyrosine kinase-1), Prealbumin, Ferritin, Osteopontin, sST2 (soluble ST2), and hsCRP (high sensitivity C-reactive protein) in a sample from a patient. Further envisaged is a method of predicting the risk of a patient to suffer from death or hospitalization, wherein said patient has heart failure and undergoes a therapy comprising a statin. The method is also based on the measurement of the level of at least one of the aforementioned markers.
Abstract translation: 本发明涉及鉴定患有心力衰竭的患者可能对包含他汀类药物的疗法有反应的方法。 该方法基于测量选自GDF-15（生长分化因子15），尿素，SHBG（性激素结合球蛋白），尿酸，PLGF（胎盘生长因子），IL-6（ 白细胞介素-6），转铁蛋白，心肌肌钙蛋白，sFlt-1（可溶性fms样酪氨酸激酶-1），前白蛋白，铁蛋白，骨桥蛋白，sST2（可溶性ST2）和hsCRP（高灵敏度C反应蛋白） 从病人。 进一步设想的是预测患者遭受死亡或住院的风险的方法，其中所述患者具有心力衰竭并经历包含他汀类药物的治疗。 该方法还基于至少一种上述标记的水平的测量。
-
-
-
-
-
-
-
-
-
Search Results
41
records
(took 0.029 seconds)
